Projects / Programmes source: ARIS

Genetic and radioisotopic methods in diagnosis and therapy of thyroid carcinoma

Research activity

Code Science Field Subfield
3.04.00  Medical sciences  Oncology   

Code Science Field
B725  Biomedical sciences  Diagnostics 
B200  Biomedical sciences  Cytology, oncology, cancerology 
B145  Biomedical sciences  Nuclear medicine, radiobiology 
thyroid carcinoma, genetic testing, mutations, RET proto-oncogen, prophylactic thyroidectomy, radioiodine therapy, prognosis, rhTSH
Evaluation (rules)
source: COBISS
Researchers (11)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  08748  MSc Damijan Bergant  Oncology  Researcher  2002 - 2004  90 
2.  10330  PhD Nikola Bešić  Oncology  Head  2002 - 2004  474 
3.  12023  PhD Marko Hočevar  Oncology  Researcher  2002 - 2004  472 
4.  15076  PhD Veronika Kloboves-Prevodnik  Oncology  Researcher  2002 - 2004  292 
5.  05278  PhD Jurij Lindtner  Oncology  Researcher  2002 - 2004  163 
6.  11771  MSc Ksenija Mahkovic-Hergouth  Oncology  Researcher  2002 - 2004  48 
7.  04401  PhD Ana Pogačnik  Oncology  Researcher  2002 - 2004  168 
8.  21757  Andreja Antonija Schwarzbartl Pevec  Oncology  Researcher  2002 - 2004  35 
9.  15828  Marko Špiler  Oncology  Researcher  2002 - 2004  52 
10.  15829  MSc Radka Tomšič-Demšar  Oncology  Researcher  2002 - 2004  32 
11.  09764  PhD Marjetka Uršič Vrščaj  Oncology  Researcher  2002 - 2004  322 
Organisations (1)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0302  Institute of Oncology Ljubljana  Ljubljana  5055733000  15,788 
Thyroid carcinoma is not biologicaly homogenous. In our prospective study, the patients and their first-degree relatives will be genetically tested, to identify the gene carriers of germline RET proto-oncogene mutation at a clinically asymptomatic stage of medullary thyroid carcinoma, in order perform prophylactic thyroidectomy in them. Our hypothesis is that some mutations of RET proto-oncogene are correlated with more aggressive clinical outcome of medullary carcinoma. Another aim of our study is to analyze correlation between different RET proto-oncogene mutations and possible appearance of multiple endocrine neoplasms. Earlier detection and treatment considerably improve the prognosis of patients with medullary carcinoma and of mutant gene carriers. It results in less aggressive treatment which is also less expensive. In our retrospective study, we will perform multivariate analysis in order to find out if more extensive thyroid surgery and common radioablation were reasons for longer survival of patients with Hürthle cell carcinoma in comparison to the survival of those with follicular carcinoma. Till now, it was not possible to use radioiodine in the treatment of patients with thyroid carcinoma and distant metastases in whom withdrawal of thyroid hormone therapy was contraindicated. In our prospective study, we will treat with recombinant human TSH and radioiodine patients: 1) with distant metastases in whom withdrawal of thyroid hormone therapy is contraindicated, and 2) in whom tumor progressed during endogenous elevation of TSH concentration. Our hypothesis is that the treatment with recombinant human TSH and radioiodine may be effective in metastatic follicular or papillary carcinoma. Our purpose is also to find out which dose of radioiodine was effective.
Views history